|
|
Br J Clin Pharmacol. 1977 June; 4(3): 343–349. | PMCID: PMC1429067 |
Amphetamines, growth hormone and narcolepsy. J D Parkes, A G Debono, P Jenner, and J Walters Abstract 1 Plasma amphetamine and growth hormone levels have been measured in eight normal and twenty-six narcoleptic subjects following a single dose of (+)-amphetamine (20 mg) or (-)-amphetamine (20 mg) by mouth. 2 Peak plasma levels and the shape of the plasma amphetamine-time curve were similar with both isomers in normal and narcoleptic subjects. 3 In most normal subjects both (+)-and (-)-amphetamine (20 mg) caused an increase in the plasma concentration of growth hormone. The two isomers were approximately equipotent in this respect. Neither (+)- nor (-)-amphetamine (20 mg) caused an increase in plasma growth hormone concentration in narcoleptics. 4 Following amphetamine (30 mg), two of six narcoleptic subjects had an increase in plasma growth hormone concentration. 5 Levodopa (250 mg) with (-)-alpha-methyldopa hydrazine 25 mg (Sinemet) by mouth, caused a rise in plasma growth hormone concentration in most normal subjects. The magnitude of the Sinemet-induced rise in plasma growth hormone concentration in narcoleptics was less than in normal subjects. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1022K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - BECKETT AH, ROWLAND M, TURNER P. INFLUENCE OF URINARY PH ON EXCRETION OF AMPHETAMINE. Lancet. 1965 Feb 6;1(7380):303–303. [PubMed]
- Besser GM, Butler PW, Landon J, Rees L. Influence of amphetamines on plasma corticosteroid and growth hormone levels in man. Br Med J. 1969 Nov 29;4(5682):528–530. [PubMed]
- Boyd AE, 3rd, Lebovitz HE, Pfeiffer JB. Stimulation of human-growth-hormone secretion by L-dopa. N Engl J Med. 1970 Dec 24;283(26):1425–1429. [PubMed]
- Bunney BS, Aghajanian GK, Roth RH. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nat New Biol. 1973 Sep 26;245(143):123–125. [PubMed]
- Campbell DB. Gas chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma, red cells and urine following therapeutic doses. J Chromatogr. 1970 Jun 24;49(3):442–447. [PubMed]
- Curzon G, Kantamaneni BD, Trigwell J. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients. Clin Chim Acta. 1972 Mar;37:335–341. [PubMed]
- Dewar AJ, Winterburn AK. Amphetamine and RNA and protein metabolism in rat brain. Brain Res. 1973 Sep 14;59:359–370. [PubMed]
- Frohman LA, Bernardis LL. Growth hormone secretion in the rat: metabolic clearance and secretion rates. Endocrinology. 1970 Feb;86(2):305–312. [PubMed]
- Graham AW, Aghajanian GK. Effects of amphetamine on single cell activity in a catecholamine nucleus, the locus coeruleus. Nature. 1971 Nov 12;234(5324):100–102. [PubMed]
- Hajos GT, Garattini S. A note on the effect of (+)- and (-)-amphetamine on lipid metabolism. J Pharm Pharmacol. 1973 May;25(5):418–419. [PubMed]
- Imura H, Kato Y, Ikeda M, Morimoto M, Yawata M. Effect of adrenergic-blocking or -stimulating agents on plasma growth hormone, immunoreactive insulin, and blood free fatty acid levels in man. J Clin Invest. 1971 May;50(5):1069–1079. [PubMed]
- Mims RB, Scott CL, Modebe O, Bethune JE. Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine. J Clin Endocrinol Metab. 1975 Feb;40(2):256–259. [PubMed]
- Nahorski SR, Rogers KJ. The role of catecholamines in the action of amphetamine and L-DOPA on cerebral energy metabolism. Neuropharmacology. 1975 Apr;14(4):283–290. [PubMed]
- Parkes JD, Debono AG, Marsden CD. Letter: Growth-hormone responses in Parkinson's disease. Lancet. 1976 Feb 28;1(7957):483–484. [PubMed]
- Parkes JD, Fenton GW. Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):1076–1081. [PubMed]
- Parkes JD, Tarsy D, Marsden CD, Bovill KT, Phipps JA, Rose P, Asselman P. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):232–237. [PubMed]
- Rees L, Butler PW, Gosling C, Besser GM. Adrenergic blockade and the corticosteroid and growth hormone responses to methylamphetamine. Nature. 1970 Nov 7;228(5271):565–566. [PubMed]
- SCHALCH DS, PARKER ML. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. [PubMed]
- Takahashi K, Takahashi S, Azumi K, Honda Y, Utena H. [Changes of plasma growth hormone level in normal and hypersomnic patients during nocturnal sleep]. Shinkei Kenkyu No Shimpo. 1971 Apr;14(4):743–754. [PubMed]
- Tanner JM. Human growth hormone. Nature. 1972 Jun 23;237(5356):433–439. [PubMed]
- van Rossum JM. Psychopharmacology of amphetamines. Psychiatr Neurol Neurochir. 1972 May–Jun;75(3):165–178. [PubMed]
- Wolf HH, Rollins DE, Rowland CR, Reigle TG. The importance of endogenous catecholamines in the activity of some CNS stimulants. Int J Neuropharmacol. 1969 Jul;8(4):319–328. [PubMed]
|
This article has been